Eikon Therapeutics, Inc.(EIKN)
Biotechnology
Oncology Biotech
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership changeShares owned | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-02-09 | Svennilson Peter 10% Owner | Purchase | +2,117,760 | +57.82%5,780,143 | $18.00 | $38,119,680 | View SEC filing | |
| 2026-02-06 | FRAZIER KENNETH C Director | Purchase | +111,111 | +100.00%111,111 | $18.00 | $1,999,998 | View SEC filing | |
| 2026-02-06 | Wolfe Josh Director, 10% Owner | Purchase | +277,776 | +4.88%5,972,786 | $18.00 | $4,999,968 | View SEC filing | |
| 2026-02-06 | Hebert Peter 10% Owner | Purchase | +277,776 | +100.00%138,888 | $18.00 | $4,999,968 | View SEC filing | |
| 2026-02-06 | Foresite Capital Fund IV, L.P. 10% Owner | Purchase | +55,555 | +4.40%1,318,983 | $18.00 | $999,990 | View SEC filing |
1-5 of 5